NZ234143A
(en)
|
1989-06-28 |
1991-10-25 |
Mcneil Ppc Inc |
Aqueous pharmaceutical suspension formulation for administering substantially insoluble pharmaceutical agents
|
GB9212308D0
(en)
*
|
1992-06-10 |
1992-07-22 |
Ici Plc |
Therapeutic compositions
|
WO1995015316A1
(en)
|
1993-11-30 |
1995-06-08 |
G. D. Searle & Co. |
Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
|
US5844092A
(en)
|
1994-03-18 |
1998-12-01 |
Genentech, Inc. |
Human TRK receptors and neurotrophic factor inhibitors
|
US5430021A
(en)
|
1994-03-18 |
1995-07-04 |
Pharmavene, Inc. |
Hydrophobic drug delivery systems
|
US5877016A
(en)
|
1994-03-18 |
1999-03-02 |
Genentech, Inc. |
Human trk receptors and neurotrophic factor inhibitors
|
US6458811B1
(en)
|
1996-03-26 |
2002-10-01 |
Eli Lilly And Company |
Benzothiophenes formulations containing same and methods
|
CA2206201A1
(en)
|
1996-05-29 |
1997-11-29 |
Yoshiaki Isobe |
Pyrazole derivatives and their pharmaceutical use
|
JP3898296B2
(ja)
|
1996-08-28 |
2007-03-28 |
ポーラ化成工業株式会社 |
ピロロピラゾロピリミジン化合物及びこれを有効成分とする医薬
|
WO1998049167A1
(en)
|
1997-04-25 |
1998-11-05 |
Takeda Chemical Industries, Ltd. |
Condensed pyridazine derivatives, their production and use
|
RU2230062C2
(ru)
|
1999-01-21 |
2004-06-10 |
Бристол-Маерс Сквибб Ко. |
Комплекс ингибитора ras-фарнезилтрансферазы, композиция ингибитора ras-фарнезилтрансферазы, фармацевтическая композиция
|
UA74546C2
(en)
|
1999-04-06 |
2006-01-16 |
Boehringer Ingelheim Ca Ltd |
Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
|
US6534085B1
(en)
|
1999-09-23 |
2003-03-18 |
Bioresponse L.L.C. |
Phytochemicals for promoting weight loss
|
US7384632B2
(en)
|
2000-06-22 |
2008-06-10 |
Genentech, Inc. |
Agonist anti-trk-C monoclonal antibodies
|
GB0028575D0
(en)
|
2000-11-23 |
2001-01-10 |
Elan Corp Plc |
Oral pharmaceutical compositions containing cyclodextrins
|
GB0121919D0
(en)
*
|
2001-09-11 |
2001-10-31 |
Astrazeneca Ab |
Chemical compounds
|
CN1531527A
(zh)
*
|
2000-12-22 |
2004-09-22 |
|
咔唑衍生物及其作为神经肽y5受体配体的用途
|
TWI312347B
(en)
|
2001-02-08 |
2009-07-21 |
Eisai R&D Man Co Ltd |
Bicyclic nitrogen-containing condensed ring compounds
|
EP2340849A1
(en)
|
2001-05-30 |
2011-07-06 |
Genentech, Inc. |
Anti-NGF antibodies for the treatment of various disorders
|
US7101572B2
(en)
|
2001-12-07 |
2006-09-05 |
Unilab Pharmatech, Ltd. |
Taste masked aqueous liquid pharmaceutical composition
|
US20030199525A1
(en)
|
2002-03-21 |
2003-10-23 |
Hirst Gavin C. |
Kinase inhibitors
|
CA2483306A1
(en)
|
2002-04-23 |
2003-11-06 |
Shionogi & Co., Ltd. |
Pyrazolo[1,5-a]pyrimidine derivative and nad(p)h oxidase inhibitor containing the same
|
US7449488B2
(en)
|
2002-06-04 |
2008-11-11 |
Schering Corporation |
Pyrazolopyrimidines as protein kinase inhibitors
|
US6982253B2
(en)
|
2002-06-05 |
2006-01-03 |
Supergen, Inc. |
Liquid formulation of decitabine and use of the same
|
ITMI20021620A1
(it)
|
2002-07-23 |
2004-01-23 |
Novuspharma Spa |
Composto ad ativita' antitumorale
|
JP4024624B2
(ja)
|
2002-08-26 |
2007-12-19 |
富士通株式会社 |
半導体装置の製造方法及び製造装置
|
US8580782B2
(en)
|
2002-09-04 |
2013-11-12 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
|
US7196078B2
(en)
|
2002-09-04 |
2007-03-27 |
Schering Corpoartion |
Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
|
US7119200B2
(en)
|
2002-09-04 |
2006-10-10 |
Schering Corporation |
Pyrazolopyrimidines as cyclin dependent kinase inhibitors
|
BRPI0314001B8
(pt)
|
2002-09-04 |
2021-05-25 |
Merck Sharp & Dohme |
pirazolopirimidinas como inibidores de cinase dependente de ciclina e composição farmacêutica compreendendo as mesmas
|
US7262199B2
(en)
|
2002-12-11 |
2007-08-28 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
US7550470B2
(en)
|
2002-12-11 |
2009-06-23 |
Merck & Co. Inc. |
Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors
|
ATE433447T1
(de)
|
2003-02-20 |
2009-06-15 |
Smithkline Beecham Corp |
Pyrimiidinverbindungen
|
GB0303910D0
(en)
|
2003-02-20 |
2003-03-26 |
Merck Sharp & Dohme |
Therapeutic agents
|
WO2004082458A2
(en)
|
2003-02-21 |
2004-09-30 |
The Johns Hopkins University |
Tyrosine kinome
|
JP2004277337A
(ja)
|
2003-03-14 |
2004-10-07 |
Sumitomo Pharmaceut Co Ltd |
ピラゾロ[1,5−a]ピリミジン誘導体
|
WO2004087707A1
(en)
|
2003-03-31 |
2004-10-14 |
Vernalis (Cambridge) Limited |
Pyrazolopyrimidine compounds and their use in medicine
|
JP2006522744A
(ja)
|
2003-04-11 |
2006-10-05 |
ノボ ノルディスク アクティーゼルスカブ |
グルココルチコイド受容体アゴニスト療法に伴う副作用を最小化するための、11β−ヒドロキシステロイドデヒドロゲナーゼ1型阻害剤およびグルココルチコイド受容体アゴニストを使用する併用療法
|
US20060094699A1
(en)
|
2003-04-11 |
2006-05-04 |
Kampen Gita Camilla T |
Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy
|
WO2004089471A2
(en)
|
2003-04-11 |
2004-10-21 |
Novo Nordisk A/S |
NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF
|
AU2004234286A1
(en)
|
2003-04-28 |
2004-11-11 |
Galpharma Co., Ltd |
Galectin 9-inducing factor
|
JO2785B1
(en)
|
2003-05-27 |
2014-03-15 |
شركة جانسين فارماسوتيكا ان. في |
Quinazoline derivatives
|
JP2005008581A
(ja)
|
2003-06-20 |
2005-01-13 |
Kissei Pharmaceut Co Ltd |
新規なピラゾロ[1,5−a]ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
|
EA009517B1
(ru)
|
2003-06-27 |
2008-02-28 |
Байер Кропсайенс Аг |
Пиразолопиримидины
|
TWI382031B
(zh)
|
2003-07-15 |
2013-01-11 |
Amgen Inc |
作為選擇性神經生長因子(ngf)通道抑制劑之人類抗-ngf中和抗體
|
US7491794B2
(en)
|
2003-10-14 |
2009-02-17 |
Intermune, Inc. |
Macrocyclic compounds as inhibitors of viral replication
|
EP1682564A1
(en)
|
2003-10-27 |
2006-07-26 |
Genelabs Technologies, Inc. |
METHODS FOR PREPARING 7-(2 -SUBSTITUTED-s-D-RIBOFURANO SYL)-4-(NR2R3)-5-(SUBSTITUTED ETHYN-1-YL)-PYRROLO 2,3-D|PYRIMIDINE DERIVATIVES
|
MY141220A
(en)
|
2003-11-17 |
2010-03-31 |
Astrazeneca Ab |
Pyrazole derivatives as inhibitors of receptor tyrosine kinases
|
US20080312192A1
(en)
|
2003-11-28 |
2008-12-18 |
Guido Bold |
Diaryl Urea Derivatives in the Treatment of Protein Kinase Dependent Diseases
|
AU2004298448B2
(en)
|
2003-12-18 |
2010-09-09 |
Janssen Pharmaceutica N.V. |
Pyrido- and pyrimidopyrimidine derivatives as anti- proliferative agents
|
JP5138938B2
(ja)
|
2003-12-19 |
2013-02-06 |
プレキシコン インコーポレーテッド |
Ret調節剤の開発のための化合物および方法
|
WO2005068424A1
(en)
|
2004-01-20 |
2005-07-28 |
Cell Therapeutics Europe S.R.L. |
Indolinone derivatives as receptor tyrosine kinase ihibitors
|
US20050222171A1
(en)
|
2004-01-22 |
2005-10-06 |
Guido Bold |
Organic compounds
|
WO2005099363A2
(en)
|
2004-03-26 |
2005-10-27 |
Whitehead Institute For Biomedical Research |
Methods of diagnosing, preventing and treating cancer metastasis
|
CN1938311A
(zh)
|
2004-03-30 |
2007-03-28 |
因特蒙公司 |
作为病毒复制抑制剂的大环化合物
|
GB0512324D0
(en)
|
2005-06-16 |
2005-07-27 |
Novartis Ag |
Organic compounds
|
PE20060664A1
(es)
|
2004-09-15 |
2006-08-04 |
Novartis Ag |
Amidas biciclicas como inhibidores de cinasa
|
AU2005304784B2
(en)
|
2004-11-04 |
2011-03-24 |
Vertex Pharmaceuticals Incorporated |
Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases
|
JO3088B1
(ar)
|
2004-12-08 |
2017-03-15 |
Janssen Pharmaceutica Nv |
مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
|
DE102005003687A1
(de)
|
2005-01-26 |
2006-07-27 |
Sphingo Tec Gmbh |
Immunoassay zur Bestimmung der Freisetzung von Neurotensin in die Zirkulation
|
DE602006015431D1
(de)
|
2005-02-16 |
2010-08-26 |
Astrazeneca Ab |
Chemische verbindungen
|
CN101119996A
(zh)
|
2005-02-16 |
2008-02-06 |
阿斯利康(瑞典)有限公司 |
化学化合物
|
MX2007011600A
(es)
|
2005-03-21 |
2007-12-07 |
Lilly Co Eli |
Compuestos de imidazopiridazina.
|
EP1877057A1
(en)
|
2005-04-27 |
2008-01-16 |
AstraZeneca AB |
Use of pyrazolyl-pyrimidine derivatives in the treatment of pain
|
JP2008540622A
(ja)
|
2005-05-16 |
2008-11-20 |
アストラゼネカ アクチボラグ |
化合物
|
CN100406650C
(zh)
|
2005-06-05 |
2008-07-30 |
徐斌 |
一种抗特大变位的模块式梳型桥梁伸缩缝装置
|
ITRM20050290A1
(it)
|
2005-06-07 |
2006-12-08 |
Lay Line Genomics Spa |
Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
|
RS52010B
(en)
|
2005-06-22 |
2012-04-30 |
Plexxikon Inc. |
DERIVATI PIROLO [2, 3-B] PIRIDINA KAO INHIBITORI PROTEIN KINAZE
|
US20070025540A1
(en)
|
2005-07-07 |
2007-02-01 |
Roger Travis |
Call center routing based on talkativeness
|
NZ565059A
(en)
|
2005-07-25 |
2011-08-26 |
Intermune Inc |
Novel macrocyclic inhibitors of hepatitus C virus replication
|
JP2009502734A
(ja)
|
2005-07-29 |
2009-01-29 |
アステラス製薬株式会社 |
Lck阻害剤としての縮合複素環
|
EP1909760A1
(en)
|
2005-08-03 |
2008-04-16 |
Eastman Chemical Company |
Tocopheryl polyethylene glycol succinate powder and process for preparing same
|
US20070191306A1
(en)
|
2005-08-17 |
2007-08-16 |
Bristol-Myers Squibb Company |
FACTOR Xa INHIBITOR FORMULATION AND METHOD
|
US7763624B2
(en)
|
2005-08-22 |
2010-07-27 |
Amgen Inc. |
Substituted pyrazolo[3,4-d]pyrimidines as ACK-1 and LCK inhibitors
|
US20070049591A1
(en)
|
2005-08-25 |
2007-03-01 |
Kalypsys, Inc. |
Inhibitors of MAPK/Erk Kinase
|
PT1919979E
(pt)
|
2005-08-25 |
2014-03-07 |
Creabilis Therapeutics Spa |
Polímeros conjugados de k-252a e seus derivados
|
DE102005042742A1
(de)
|
2005-09-02 |
2007-03-08 |
Schering Ag |
Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
|
US20070078136A1
(en)
|
2005-09-22 |
2007-04-05 |
Bristol-Myers Squibb Company |
Fused heterocyclic compounds useful as kinase modulators
|
JP5152922B2
(ja)
|
2005-10-06 |
2013-02-27 |
メルク・シャープ・アンド・ドーム・コーポレーション |
プロテインキナーゼを阻害するためのピラゾロ[1,5−a]ピリミジン誘導体の使用およびプロテインキナーゼを阻害する方法
|
CN101316847A
(zh)
|
2005-10-06 |
2008-12-03 |
先灵公司 |
用作蛋白激酶抑制剂的吡唑并(1,5a)嘧啶化合物
|
JP5030961B2
(ja)
|
2005-10-11 |
2012-09-19 |
サーントゥル ナシオナル ドゥ ラ ルシェルシュ シャーンティフィク |
細胞のアポトーシスの検出および定量化用の化合物およびキット
|
JP2009511595A
(ja)
|
2005-10-11 |
2009-03-19 |
インターミューン・インコーポレーテッド |
C型肝炎ウイルスの複製を阻害する化合物および方法
|
WO2007048065A2
(en)
|
2005-10-21 |
2007-04-26 |
Exelixis, Inc. |
Pyrimidinones as casein kinase ii (ck2) modulators
|
WO2007057399A2
(en)
|
2005-11-15 |
2007-05-24 |
Boehringer Ingelheim International Gmbh |
Treatment of cancer with indole derivatives
|
GB0524436D0
(en)
|
2005-11-30 |
2006-01-11 |
Novartis Ag |
Organic compounds
|
US20070166336A1
(en)
|
2005-12-13 |
2007-07-19 |
David Delmarre |
Stable and palatable oral liquid sumatriptan compositions
|
EP1968579A1
(en)
|
2005-12-30 |
2008-09-17 |
Astex Therapeutics Limited |
Pharmaceutical compounds
|
WO2007084815A2
(en)
|
2006-01-19 |
2007-07-26 |
Janssen Pharmaceutica, N.V. |
Substituted thienopyrimidine kinase inhibitors
|
US20090227598A1
(en)
|
2006-01-24 |
2009-09-10 |
Buser-Doepner Carolyn A |
Ret Tyrosine Kinase Inhibition
|
WO2007102679A1
(en)
|
2006-03-06 |
2007-09-13 |
Je Il Pharmaceutical Co., Ltd. |
Novel thienopyrimidine derivatives or pharmaceutically acceptable salts thereof, process for the preparation thereof and pharmaceutical composition comprising the same
|
JP2009529047A
(ja)
*
|
2006-03-07 |
2009-08-13 |
アレイ バイオファーマ、インコーポレイテッド |
ヘテロ二環系ピラゾール化合物およびその使用
|
JP5261370B2
(ja)
|
2006-03-27 |
2013-08-14 |
ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ |
キナーゼ阻害剤としてのピリジル及びピリミジニル置換されたピロール、チオフェン及びフラン誘導体
|
GB0606805D0
(en)
|
2006-04-04 |
2006-05-17 |
Novartis Ag |
Organic compounds
|
DE602007007323D1
(de)
|
2006-04-26 |
2010-08-05 |
Hoffmann La Roche |
Thienoä3,2-düpyrimidin-derivat geeignet als pi3k inhibitor
|
CN104706637A
(zh)
|
2006-05-18 |
2015-06-17 |
卫材R&D管理有限公司 |
针对甲状腺癌的抗肿瘤剂
|
EP1873157A1
(en)
|
2006-06-21 |
2008-01-02 |
Bayer Schering Pharma Aktiengesellschaft |
Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
|
TWI419889B
(zh)
|
2006-07-05 |
2013-12-21 |
Mitsubishi Tanabe Pharma Corp |
吡唑并〔1,5-a〕嘧啶化合物
|
BRPI0714665A2
(pt)
|
2006-08-04 |
2012-03-13 |
Takeda Pharmaceutical Company Limited |
Composto, pró-droga, agente farmacêutico, e, método para a profilaxia ou tratamento do câncer
|
EP2058309A4
(en)
|
2006-08-04 |
2010-12-22 |
Takeda Pharmaceutical |
CONDENSED HETEROCYCLIC COMPOUND
|
US7531539B2
(en)
|
2006-08-09 |
2009-05-12 |
Bristol-Myers Squibb Company |
Pyrrolotriazine kinase inhibitors
|
WO2008030579A2
(en)
|
2006-09-07 |
2008-03-13 |
Biogen Idec Ma Inc. |
Irak modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder
|
WO2008031551A2
(en)
|
2006-09-12 |
2008-03-20 |
Novartis Forschungsstiftung, Zweigniederlassung |
Non-neuroendocrine cancer therapy
|
US20090286779A1
(en)
|
2006-09-29 |
2009-11-19 |
Novartis Ag |
Pyrazolopyrimidines as lipid kinase inhibitors
|
RU2009120389A
(ru)
|
2006-10-30 |
2010-12-10 |
Новартис АГ (CH) |
Гетероциклические соединения в качестве противовоспалительных агентов
|
JP5357763B2
(ja)
|
2006-11-06 |
2013-12-04 |
トレロ ファーマシューティカルズ, インコーポレイテッド |
イミダゾ[1,2−b]ピリダジン誘導体およびピラゾロ[1,5−a]ピリダジン誘導体およびプロテインキナーゼインヒビターとしてのこれらの使用
|
PE20121126A1
(es)
|
2006-12-21 |
2012-08-24 |
Plexxikon Inc |
Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
|
MX2009006688A
(es)
|
2006-12-21 |
2009-06-30 |
Plexxikon Inc |
Compuestos y metodos para modulacion de cinasas, e indicaciones para ello.
|
WO2008079909A1
(en)
|
2006-12-21 |
2008-07-03 |
Plexxikon, Inc. |
Pyrrolo [2,3-b] pyridines as kinase modulators
|
US7820684B2
(en)
|
2007-03-01 |
2010-10-26 |
Supergen, Inc. |
Pharmaceutical formulations comprising salts of a protein kinase inhibitor and methods of using same
|
US20080234267A1
(en)
|
2007-03-20 |
2008-09-25 |
Karen Elizabeth Lackey |
Compounds and Methods of Treatment
|
US20080234262A1
(en)
|
2007-03-21 |
2008-09-25 |
Wyeth |
Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
|
CA2682016A1
(en)
|
2007-03-28 |
2008-10-02 |
Inovacia Ab |
Pyrazolo [1,5-a]pyrimidines as inhibitors of stearoyl-coa desaturase
|
JP5374492B2
(ja)
|
2007-04-03 |
2013-12-25 |
アレイ バイオファーマ、インコーポレイテッド |
受容体チロシンキナーゼ阻害薬としてのイミダゾ[1,2−a]ピリジン化合物
|
CA2686382C
(en)
|
2007-05-04 |
2013-09-17 |
Irm Llc |
Phenylaminopyrimidine derivatives and compositions thereof as c-kit and pdgfr kinase inhibitors
|
ES2435454T3
(es)
|
2007-06-21 |
2013-12-19 |
Janssen Pharmaceutica, N.V. |
Indolin-2-onas y aza-indolin-2-onas
|
EP2074118A2
(en)
|
2007-07-09 |
2009-07-01 |
AstraZeneca AB |
Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
|
CA2695004C
(en)
|
2007-07-17 |
2016-01-19 |
Plexxikon, Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
US8293747B2
(en)
|
2007-07-19 |
2012-10-23 |
Merck Sharp & Dohme Corp. |
Heterocyclic amide compounds as protein kinase inhibitors
|
EP2176231B1
(en)
|
2007-07-20 |
2016-10-19 |
Nerviano Medical Sciences S.r.l. |
Substituted indazole derivatives active as kinase inhibitors
|
WO2009017838A2
(en)
|
2007-08-01 |
2009-02-05 |
Exelixis, Inc. |
Combinations of jak-2 inhibitors and other agents
|
EP2572729A3
(en)
|
2007-08-10 |
2013-06-05 |
Regeneron Pharmaceuticals, Inc. |
High affinity human antibodies to human nerve growth factor
|
MX2010004260A
(es)
|
2007-10-16 |
2010-04-30 |
Wyeth Llc |
Compuestos de tienopirimidina y pirazolopirimidina y su uso como inhibidores de mtor cinasa y pi3 cinasa.
|
CA2703329A1
(en)
|
2007-10-23 |
2009-04-30 |
Novartis Ag |
Use of trkb antibodies for the treatment of respiratory disorders
|
WO2009060197A1
(en)
|
2007-11-08 |
2009-05-14 |
Centro Nacional De Investigaciones Oncologicas (Cnio) |
Imidazopyridazines for use as protein kinase inhibitors
|
CN101970440A
(zh)
|
2007-11-28 |
2011-02-09 |
先灵公司 |
作为蛋白激酶抑制剂的2-氟吡唑并[1,5-a]嘧啶类
|
EP2215091B1
(en)
|
2007-12-04 |
2016-03-30 |
Nerviano Medical Sciences S.r.l. |
Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
|
CA2712298C
(en)
|
2008-01-17 |
2015-11-24 |
Irm Llc |
Improved anti-trkb antibodies
|
JP2009203226A
(ja)
|
2008-01-31 |
2009-09-10 |
Eisai R & D Management Co Ltd |
ピリジン誘導体およびピリミジン誘導体を含有するレセプターチロシンキナーゼ阻害剤
|
AU2009221177B2
(en)
|
2008-03-03 |
2013-05-30 |
Ucb Biopharma Sprl |
Pharmaceutical solutions, process of preparation and therapeutic uses
|
KR100963051B1
(ko)
|
2008-03-14 |
2010-06-09 |
광동제약 주식회사 |
입자크기가 조절된 술포데히드로아비에트산을 함유한쓴맛이 저감된 경구용 액상 조성물
|
JP5767101B2
(ja)
|
2008-03-28 |
2015-08-19 |
ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ |
キナーゼ阻害剤として活性な3,4−ジヒドロ−2h−ピラジノ[1,2−a]インドール−1−オン誘導体、これらの調製方法、およびこれらを含む医薬組成物
|
US20090275622A1
(en)
|
2008-04-30 |
2009-11-05 |
Prasoona Linga |
Nizatidine formulations
|
CN102056927B
(zh)
|
2008-05-13 |
2014-06-25 |
Irm责任有限公司 |
作为激酶抑制剂的稠合含氮杂环及其组合物
|
PE20091846A1
(es)
|
2008-05-19 |
2009-12-16 |
Plexxikon Inc |
DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS
|
US8158636B2
(en)
|
2008-05-19 |
2012-04-17 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
CA2725185C
(en)
|
2008-05-23 |
2016-10-25 |
Novartis Ag |
Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
|
AU2009257635A1
(en)
|
2008-06-10 |
2009-12-17 |
Plexxikon, Inc. |
5H-Pyrrolo [2,3-b] pyrazine derivatives for kinase modulation, and indications therefor
|
US8946226B2
(en)
|
2008-07-29 |
2015-02-03 |
Nerviano Medical Sciences S.R.L. |
Use of CDK inhibitor for the treatment of glioma
|
ES2536730T3
(es)
|
2008-09-19 |
2015-05-28 |
Nerviano Medical Sciences S.R.L. |
Derivados de 3,4-dihidro-2H-pirrolo[1,2-a]pirazin-1-ona
|
CA2952692C
(en)
|
2008-09-22 |
2020-04-28 |
Array Biopharma Inc. |
Substituted imidazo[1,2b]pyridazine compounds
|
TWI458729B
(zh)
|
2008-10-22 |
2014-11-01 |
Array Biopharma Inc |
作為TRK激酶抑制劑之經取代吡唑并〔1,5-a〕嘧啶化合物
|
EP2962566A1
(en)
|
2008-10-31 |
2016-01-06 |
Genentech, Inc. |
Pyrazolopyrimidine jak inhibitor compounds and methods
|
EP2376084B1
(en)
|
2008-11-24 |
2013-07-17 |
Nerviano Medical Sciences S.r.l. |
CDK inhibitor for the treatment of mesothelioma
|
JO3265B1
(ar)
|
2008-12-09 |
2018-09-16 |
Novartis Ag |
مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
|
PL2881402T3
(pl)
|
2009-02-12 |
2017-10-31 |
Cell Signaling Technology Inc |
Ekspresja zmutowanej ROS w ludzkim raku wątroby
|
WO2010111527A1
(en)
|
2009-03-26 |
2010-09-30 |
Plexxikon, Inc. |
Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use
|
EP2443117B1
(en)
|
2009-06-15 |
2016-03-23 |
Nerviano Medical Sciences S.r.l. |
Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors
|
AR077468A1
(es)
|
2009-07-09 |
2011-08-31 |
Array Biopharma Inc |
Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
|
WO2011084486A1
(en)
|
2009-12-21 |
2011-07-14 |
Epitherix, Llc |
1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
|
EP2528918B1
(en)
|
2010-01-29 |
2014-09-10 |
Nerviano Medical Sciences S.r.l. |
6,7-dihydroimidazo[1,5-a]pyrazin-8(5h)-one derivatives as protein kinase modulators
|
EP2536414B1
(en)
|
2010-02-18 |
2016-07-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for preventing cancer metastasis
|
CA2795776A1
(en)
|
2010-04-06 |
2011-10-13 |
Caris Life Sciences Luxembourg Holdings, S.A.R.L. |
Circulating biomarkers for disease
|
US8383793B2
(en)
|
2010-04-15 |
2013-02-26 |
St. Jude Children's Research Hospital |
Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors
|
TWI510487B
(zh)
|
2010-04-21 |
2015-12-01 |
Plexxikon Inc |
用於激酶調節的化合物和方法及其適應症
|
CR20170098A
(es)
|
2010-05-20 |
2017-07-17 |
Array Biopharma Inc |
Compuestos macrociclicos como inhibidores de quinasa trk
|
WO2011156588A1
(en)
|
2010-06-09 |
2011-12-15 |
Dana-Farber Cancer Institute, Inc. |
A mek 1 mutation conferring resistance to raf and mek inhibitors
|
HRP20220405T1
(hr)
|
2010-08-19 |
2022-05-27 |
Zoetis Belgium S.A. |
Protutijela protiv ngf i njihova upotreba
|
US8637516B2
(en)
|
2010-09-09 |
2014-01-28 |
Irm Llc |
Compounds and compositions as TRK inhibitors
|
WO2012034095A1
(en)
|
2010-09-09 |
2012-03-15 |
Irm Llc |
Compounds and compositions as trk inhibitors
|
JP2014005206A
(ja)
|
2010-10-22 |
2014-01-16 |
Astellas Pharma Inc |
アリールアミノヘテロ環カルボキサミド化合物
|
KR102025848B1
(ko)
|
2010-12-01 |
2019-11-05 |
앨더바이오 홀딩스 엘엘씨 |
항―ngf 조성물 및 그의 용도
|
CN103339134B
(zh)
|
2011-01-26 |
2015-12-23 |
内尔维阿诺医学科学有限公司 |
三环吡咯并衍生物、它们的制备方法和它们作为激酶抑制剂的应用
|
US8916577B2
(en)
|
2011-01-26 |
2014-12-23 |
Nerviano Medical Sciences S.R.L. |
Tricyclic derivatives, process for their preparation and their use as kinase inhibitors
|
ES2696023T3
(es)
|
2011-02-07 |
2019-01-11 |
Plexxikon Inc |
Compuestos y métodos para la modulación de quinasas e indicaciones para ello
|
ES2580961T3
(es)
|
2011-02-24 |
2016-08-30 |
Nerviano Medical Sciences S.R.L. |
Derivados Tiazolilfenil-bencenosulfonamido como Inhibidores de Cinasa
|
PE20140378A1
(es)
|
2011-02-25 |
2014-03-28 |
Irm Llc |
Compuestos y composiciones como inhibidores de la trk
|
US9284298B2
(en)
|
2011-04-11 |
2016-03-15 |
Nerviano Medical Sciences S.R.L. |
Pyrazolyl-pyrimidine derivatives as kinase inhibitors
|
US9283224B2
(en)
|
2011-04-19 |
2016-03-15 |
Nerviano Medical Sciences S.R.L. |
Substituted pyrimidinyl-pyrroles active as kinase inhibitors
|
US9408850B2
(en)
|
2011-05-12 |
2016-08-09 |
Nerviano Medical Sciences S.R.L. |
Substituted indazole derivatives active as kinase inhibitors
|
CN103649076B
(zh)
|
2011-05-13 |
2015-09-09 |
阵列生物制药公司 |
作为trka激酶抑制剂的吡咯烷基脲和吡咯烷基硫脲化合物
|
EP2736514B1
(en)
|
2011-07-28 |
2017-10-18 |
Nerviano Medical Sciences S.r.l. |
Alkynyl substituted pyrimidinyl-pyrroles active as kinases inhibitors
|
JP6063945B2
(ja)
|
2011-10-07 |
2017-01-18 |
ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ |
キナーゼ阻害剤としての4−アルキル置換3,4−ジヒドロピロロ[1,2−a]ピラジン−1(2H)−オン誘導体
|
WO2013050446A1
(en)
|
2011-10-07 |
2013-04-11 |
Nerviano Medical Sciences S.R.L. |
SUBSTITUTED 3,4-DIHYDROPYRROLO[1,2-a]PYRAZIN-1(2H)-ONE DERIVATIVES AS KINASES INHIBITORS
|
WO2013059740A1
(en)
|
2011-10-21 |
2013-04-25 |
Foundation Medicine, Inc. |
Novel alk and ntrk1 fusion molecules and uses thereof
|
JP2014533286A
(ja)
|
2011-11-14 |
2014-12-11 |
テサロ, インコーポレイテッド |
特定のチロシンキナーゼの調節
|
MX356401B
(es)
|
2011-12-12 |
2018-05-21 |
Dr Reddys Laboratories Ltd |
Pirazol[1,5-a]piridina sustituida como inhibidores de la cinasa del receptor de tropomiosina (trk).
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
ES2605388T3
(es)
|
2012-04-26 |
2017-03-14 |
Ono Pharmaceutical Co., Ltd. |
Compuesto inhibidor de Trk
|
JP2013226108A
(ja)
|
2012-04-27 |
2013-11-07 |
Astellas Pharma Inc |
新規ntrk2活性化変異の検出法
|
AU2013265288B2
(en)
|
2012-05-23 |
2017-12-21 |
Nerviano Medical Sciences S.R.L. |
Process for the preparation of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
|
TWI585088B
(zh)
|
2012-06-04 |
2017-06-01 |
第一三共股份有限公司 |
作爲激酶抑制劑之咪唑并[1,2-b]嗒衍生物
|
EP2866802B1
(en)
|
2012-06-28 |
2016-07-27 |
Johnson & Johnson Consumer Inc. |
Racecadotril liquid compositions
|
RS62233B1
(sr)
|
2012-07-11 |
2021-09-30 |
Blueprint Medicines Corp |
Inhibitori receptora fibroblast faktora rasta
|
KR20150032340A
(ko)
|
2012-07-24 |
2015-03-25 |
파마시클릭스, 인코포레이티드 |
브루톤 티로신 키나제(btk)의 억제제에 대한 내성과 관련된 돌연변이
|
EP2689778A1
(en)
|
2012-07-27 |
2014-01-29 |
Pierre Fabre Medicament |
Derivatives of azaindoles or diazaindoles for treating pain
|
JP6276762B2
(ja)
|
2012-08-02 |
2018-02-07 |
ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ |
キナーゼ阻害剤として活性な置換ピロール類
|
WO2014036387A2
(en)
|
2012-08-31 |
2014-03-06 |
The Regents Of The University Of Colorado |
Methods for diagnosis and treatment of cancer
|
CN114129566A
(zh)
|
2012-09-07 |
2022-03-04 |
埃克塞里艾克西斯公司 |
用于治疗肺腺癌的met、vegfr和ret的抑制剂
|
US20140084039A1
(en)
|
2012-09-24 |
2014-03-27 |
Electro Scientific Industries, Inc. |
Method and apparatus for separating workpieces
|
JP2014082984A
(ja)
|
2012-10-23 |
2014-05-12 |
Astellas Pharma Inc |
新規ntrk2活性化変異の検出法
|
EP4223770A3
(en)
|
2012-11-05 |
2023-10-18 |
Foundation Medicine, Inc. |
Novel fusion molecules and uses thereof
|
AU2013337277B2
(en)
|
2012-11-05 |
2018-03-08 |
Foundation Medicine, Inc. |
Novel NTRK1 fusion molecules and uses thereof
|
CN104870446B
(zh)
|
2012-11-07 |
2019-08-13 |
内尔维阿诺医学科学有限公司 |
取代的嘧啶基和吡啶基吡咯并吡啶酮类、其制备方法及其作为激酶抑制剂的用途
|
WO2014078331A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
US9546156B2
(en)
|
2012-11-13 |
2017-01-17 |
Array Biopharma Inc. |
N-bicyclic aryl,N'-pyrazolyl urea, thiourea, guanidine cyanoguanidine compounds as TrkA kinase inhibitors
|
SG11201503728XA
(en)
|
2012-11-13 |
2015-06-29 |
Array Biopharma Inc |
N-pyrrolidinyl, n'-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
AU2013344886B2
(en)
|
2012-11-13 |
2017-06-29 |
Array Biopharma Inc. |
Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain
|
US9790178B2
(en)
|
2012-11-13 |
2017-10-17 |
Array Biopharma Inc. |
Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
|
WO2014078322A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
WO2014078417A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
US9828360B2
(en)
|
2012-11-13 |
2017-11-28 |
Array Biopharma Inc. |
Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
|
WO2014078408A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
WO2014078325A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
JP2016502536A
(ja)
|
2012-11-29 |
2016-01-28 |
イェダ リサーチ アンド デベロップメント カンパニー リミテッド |
腫瘍転移を防止し、がんを処置および予後診断し、推定転移阻害剤である薬剤を同定する方法
|
US9447135B2
(en)
|
2012-12-14 |
2016-09-20 |
University Of Kentucky Research Foundation |
Semi-synthetic mithramycin derivatives with anti-cancer activity
|
US9127055B2
(en)
|
2013-02-08 |
2015-09-08 |
Astellas Pharma Inc. |
Method of treating pain with anti-human NGF antibody
|
SG10201700808UA
(en)
|
2013-02-19 |
2017-02-27 |
Ono Pharmaceutical Co |
Trk-INHIBITING COMPOUND
|
US20160010068A1
(en)
|
2013-02-22 |
2016-01-14 |
Boris C. Bastian |
Fusion polynucleotides and fusion polypeptides associated with cancer and particularly melanoma and their uses as therapeutic and diagnostic targets
|
WO2014134096A1
(en)
|
2013-02-27 |
2014-09-04 |
Oregon Health & Science University |
Methods of treating cancers characterized by aberrent ros1 activity
|
US9499522B2
(en)
|
2013-03-15 |
2016-11-22 |
Blueprint Medicines Corporation |
Compositions useful for treating disorders related to kit
|
ES2900301T3
(es)
|
2013-03-15 |
2022-03-16 |
Novartis Ag |
Biomarcadores asociados con la inhibición de BRM
|
KR20150129847A
(ko)
|
2013-03-15 |
2015-11-20 |
더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 |
융합 단백질 및 이들의 방법
|
WO2014152777A2
(en)
|
2013-03-15 |
2014-09-25 |
Insight Genetics, Inc. |
Methods and compositions for the diagnosis and treatment of cancers resistant to ros1 inhibitors
|
CN113337604A
(zh)
|
2013-03-15 |
2021-09-03 |
莱兰斯坦福初级大学评议会 |
循环核酸肿瘤标志物的鉴别和用途
|
AR095308A1
(es)
|
2013-03-15 |
2015-10-07 |
Glaxosmithkline Ip Dev Ltd |
Compuesto de 2-piridona, composición farmacéutica que lo comprende y su uso para preparar un medicamento
|
US10072298B2
(en)
|
2013-04-17 |
2018-09-11 |
Life Technologies Corporation |
Gene fusions and gene variants associated with cancer
|
CN105378110A
(zh)
|
2013-04-17 |
2016-03-02 |
生命技术公司 |
与癌症相关的基因融合体和基因变异体
|
JP6397897B2
(ja)
|
2013-05-14 |
2018-09-26 |
ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ |
ピロロ[2,3−d]ピリミジン誘導体、その製造方法及びキナーゼ阻害剤としてのその使用
|
RU2015149937A
(ru)
|
2013-05-30 |
2017-07-06 |
Плексксикон Инк. |
Соединения для модулирования киназы и показания к их применению
|
US9783524B2
(en)
|
2013-07-11 |
2017-10-10 |
Betta Pharmaceuticals Co., Ltd. |
Protein tyrosine kinase modulators and methods of use
|
JP6534930B2
(ja)
|
2013-07-26 |
2019-06-26 |
公益財団法人がん研究会 |
Ntrk3融合体の検出法
|
US10875930B2
(en)
|
2013-07-30 |
2020-12-29 |
Blueprint Medicines Corporation |
PIK3C2G fusions
|
US10407509B2
(en)
|
2013-07-30 |
2019-09-10 |
Blueprint Medicines Corporation |
NTRK2 fusions
|
WO2015039006A1
(en)
|
2013-09-16 |
2015-03-19 |
The General Hospital Corporation |
Methods of treating cancer
|
US9334263B2
(en)
|
2013-10-17 |
2016-05-10 |
Blueprint Medicines Corporation |
Compositions useful for treating disorders related to kit
|
DK3057969T3
(en)
|
2013-10-17 |
2018-09-24 |
Blueprint Medicines Corp |
COMPOSITIONS USED FOR TREATMENT OF DISEASES RELATED TO ENZYMETE KIT
|
KR20160065986A
(ko)
|
2013-10-24 |
2016-06-09 |
조지타운 유니버시티 |
암 치료용 방법 및 조성물
|
CN110028491B
(zh)
|
2013-10-25 |
2022-02-11 |
缆图药品公司 |
纤维母细胞生长因子受体抑制剂
|
WO2015064621A1
(ja)
|
2013-10-29 |
2015-05-07 |
公益財団法人がん研究会 |
新規融合体及びその検出法
|
WO2015108992A1
(en)
|
2014-01-15 |
2015-07-23 |
Blueprint Medicines Corporation |
Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
|
EA031863B1
(ru)
|
2014-01-24 |
2019-03-29 |
ТиПи ТЕРАПЬЮТИКС, ИНК. |
Диарильные макроциклы в качестве модуляторов протеинкиназ
|
SI3102555T1
(sl)
|
2014-02-05 |
2021-11-30 |
VM Oncology LLC |
Sestavki spojin in njihove uporabe
|
US10231965B2
(en)
|
2014-02-20 |
2019-03-19 |
Ignyta, Inc. |
Molecules for administration to ROS1 mutant cancer cells
|
EP3132054B1
(en)
|
2014-04-18 |
2021-06-30 |
Blueprint Medicines Corporation |
Met fusions
|
US20170044622A1
(en)
|
2014-04-18 |
2017-02-16 |
Blueprint Medicines Corporation |
Pik3ca fusions
|
NZ727418A
(en)
|
2014-05-15 |
2023-03-31 |
Array Biopharma Inc |
1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor
|
WO2015183836A1
(en)
|
2014-05-27 |
2015-12-03 |
Brian Haynes |
Compositions, methods, and uses related to ntrk2-tert fusions
|
WO2015183837A1
(en)
|
2014-05-27 |
2015-12-03 |
Brian Haynes |
Compositions, methods, and uses related to ntrk2-tert fusions
|
WO2015184443A1
(en)
|
2014-05-30 |
2015-12-03 |
The Regents Of The University Of Colorado |
Activating ntrk1 gene fusions predictive of kinase inhibitor therapy
|
EP3155118A1
(en)
|
2014-06-10 |
2017-04-19 |
Blueprint Medicines Corporation |
Pkn1 fusions
|
EP3155131B1
(en)
|
2014-06-10 |
2020-02-12 |
Blueprint Medicines Corporation |
Raf1 fusions
|
US10370724B2
(en)
|
2014-07-17 |
2019-08-06 |
Blueprint Medicines Corporation |
PRKC fusions
|
EP3169804B3
(en)
|
2014-07-17 |
2019-09-18 |
Blueprint Medicines Corporation |
Fgr fusions
|
US10370723B2
(en)
|
2014-07-17 |
2019-08-06 |
Blueprint Medicines Corporation |
TERT fusions
|
EP3185870A4
(en)
|
2014-08-01 |
2018-06-20 |
Pharmacyclics LLC |
Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor
|
WO2016022569A1
(en)
|
2014-08-04 |
2016-02-11 |
Blueprint Medicines Corporation |
Compositions useful for treating disorders related to kit
|
KR20170042591A
(ko)
|
2014-08-18 |
2017-04-19 |
오노 야꾸힝 고교 가부시키가이샤 |
Trk 저해 화합물의 산부가염
|
SG11201702401RA
(en)
|
2014-10-14 |
2017-04-27 |
Novartis Ag |
Antibody molecules to pd-l1 and uses thereof
|
ES2792036T3
(es)
|
2014-11-14 |
2020-11-06 |
Nerviano Medical Sciences Srl |
Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de cinasa
|
PL3699181T3
(pl)
*
|
2014-11-16 |
2023-05-22 |
Array Biopharma, Inc. |
Postać krystaliczna wodorosiarczanu (s)-n-(5-((r)-2-(2,5-difluorofenylo) - pirolidyn-1-ylo)-pirazolo[1,5-a]pirimidyn-3-ylo)-3-hydroksypirolidyno-1-karboksyamidu
|
US20170356052A1
(en)
|
2014-11-18 |
2017-12-14 |
Blueprint Medicines Corporation |
Prkacb fusions
|
US9701681B2
(en)
|
2014-12-15 |
2017-07-11 |
Cmg Pharmaceutical Co., Ltd. |
Fused ring heteroaryl compounds and their use as Trk inhibitors
|
IL294183B2
(en)
|
2015-05-20 |
2023-10-01 |
Dana Farber Cancer Inst Inc |
shared neoantigens
|
CA2987281A1
(en)
|
2015-05-29 |
2016-12-08 |
Ignyta, Inc. |
Compositions and methods for treating patients with rtk mutant cells
|
BR112017025773A2
(pt)
|
2015-06-01 |
2018-08-14 |
Loxo Oncology Inc |
métodos de diagnóstico e tratamento de câncer
|
AU2015101722A4
(en)
|
2015-06-19 |
2016-05-19 |
Macau University Of Science And Technology |
Oncogenic ros1 and alk kinase inhibitor
|
US9782400B2
(en)
|
2015-06-19 |
2017-10-10 |
Macau University Of Science And Technology |
Oncogenic ROS1 and ALK kinase inhibitor
|
GB201511546D0
(en)
|
2015-07-01 |
2015-08-12 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
|
US10316044B2
(en)
|
2015-07-02 |
2019-06-11 |
Tp Therapeutics, Inc. |
Chiral diaryl macrocycles as modulators of protein kinases
|
SG11201803438XA
(en)
|
2015-10-26 |
2018-05-30 |
Univ Colorado Regents |
Point mutations in trk inhibitor-resistant cancer and methods relating to the same
|
WO2017127835A2
(en)
|
2016-01-22 |
2017-07-27 |
The Medicines Company |
Aqueous formulations and methods of preparation and use thereof
|
WO2017155018A1
(ja)
|
2016-03-11 |
2017-09-14 |
小野薬品工業株式会社 |
Trk阻害剤抵抗性の癌治療剤
|
KR20180129911A
(ko)
|
2016-04-04 |
2018-12-05 |
록쏘 온콜로지, 인코포레이티드 |
소아암을 치료하는 방법
|
US10045991B2
(en)
|
2016-04-04 |
2018-08-14 |
Loxo Oncology, Inc. |
Methods of treating pediatric cancers
|
SG11201808559PA
(en)
|
2016-04-04 |
2018-10-30 |
Loxo Oncology Inc |
Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
|
EP3445361A1
(en)
|
2016-04-19 |
2019-02-27 |
Exelixis, Inc. |
Triple negative breast cancer treatment method
|
JP7443057B2
(ja)
|
2016-05-18 |
2024-03-05 |
ロクソ オンコロジー, インコーポレイテッド |
(S)-N-(5-((R)-2-(2,5-ジフルオロフェニル)ピロリジン-1-イル)-ピラゾロ[1,5-a]ピリミジン-3-イル)-3-ヒドロキシピロリジン-1-カルボキサミドの調製
|
WO2017201156A1
(en)
|
2016-05-18 |
2017-11-23 |
Duke University |
Method of treating kras wild-type metastatic colorectal cell carcinoma using cabozantinib plus panitumumab
|
JOP20190092A1
(ar)
|
2016-10-26 |
2019-04-25 |
Array Biopharma Inc |
عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
|
JOP20190213A1
(ar)
|
2017-03-16 |
2019-09-16 |
Array Biopharma Inc |
مركبات حلقية ضخمة كمثبطات لكيناز ros1
|
US20190247398A1
(en)
|
2017-10-26 |
2019-08-15 |
Array Biopharma Inc. |
Formulations of a macrocyclic trk kinase inhibitor
|
MA52218A
(fr)
|
2018-03-29 |
2021-02-17 |
Loxo Oncology Inc |
Traitement de cancers associés à trk
|